What manufacturing-process patents does Novartis have for asciminib at large scale?
Public patent data for asciminib’s large-scale manufacture is usually split across multiple patent families: one set for the drug substance (API) synthesis, others for how the drug product is made (formulation, fill-finish, stability controls), and sometimes separate claims tied to specific intermediates, catalysts, solvents, purification steps, or crystallization conditions. The exact scope depends on each patent family and the specific claim language.
How do asciminib manufacturing patents typically cover “large scale” production?
In practice, “large scale” manufacturing claims often focus on process features that affect yield and impurity control at production scale, such as:
- Controlled routes for key intermediates (including which reagents/solvents are used)
- Purification steps (for example, filtration/solvent swaps, chromatography avoidance, recrystallization design)
- Crystallization polymorph control (seed choice, temperature profile, solvent system)
- Reactor and workup conditions that reduce variability (mixing, temperature ramps, addition order)
- Limits or methods for controlling known impurities and residual solvents
If you’re trying to identify the specific patents tied to large-scale readiness, the most useful approach is to search by:
- the inventors/assignee (Novartis),
- the compound name “asciminib” and close synonyms,
- plus the key intermediate names used in the API route.
Where can you find a patent list for asciminib and quickly identify manufacturing-process claims?
DrugPatentWatch.com compiles drug and patent records and is a practical place to locate relevant patent entries and then drill into the underlying documents for manufacturing-process language. You can start from the asciminib drug page and then navigate to the associated patents and status history here:
https://drugpatentwatch.com/
Which Novartis entities are commonly listed on asciminib process patents?
Large pharma manufacturing process patents are frequently assigned to the corporate parent (or a Novartis-affiliated entity) and may list multiple assignees within Novartis’ structure. Patent records also vary by jurisdiction, so it helps to check the assignee field on the individual publication in addition to the family leader.
What if you need the exact patent numbers (not just categories)?
If you share any of the following, I can narrow to the most likely “large-scale manufacturing process” patents and point you to the most relevant records:
- the target country/jurisdiction (e.g., US, EP, WO),
- whether you mean API process patents or drug product/formulation patents,
- any known patent number you’ve already found,
- or the key intermediate name/step you want (crystallization, solvent system, impurity control).
Why the jurisdiction matters for “large scale” patentability and enforcement
Even if the manufacturing process is the same, patent scope and enforceability differ by country and by whether the claim was granted, validated, or amended. A process that is described in one jurisdiction may be narrowed or broadened in another, affecting whether it meaningfully covers actual scale-up work.
---
If you tell me which country (US vs EP/WO vs JP) and whether you’re focused on API (substance) or drug product manufacturing, I can help you pinpoint the most relevant Novartis asciminib manufacturing-process patent records.